Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28278088 | 0.98 | KDM4E (0.47) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| Thiophene SCHEMBL9063467 | 0.93 | KDM4E (0.44) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL13762461 | 0.74 | KDM4E (0.70) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL12906161 | 0.69 | NOTUM (0.59) | KDM4EALDH1A1HPGDNOTUMMAPT | |
| SCHEMBL8870884 | 0.68 | NOTUM (0.50) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL7058937 | 0.68 | KDM4E (0.67) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL22471879 | 0.68 | ATAD2 (0.61) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL4897 | 0.68 | ALDH1A1 (0.49) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9454334 | 0.67 | ALDH1A1 (0.44) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL1272658 | 0.67 | KDM4E (0.56) | KDM4ERAB9AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884682-B2 | Compounds and their uses as MIF inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-01-30 | — | — | US | claimed |
| CN-109293650-A | Using DMF as one step of carbon source construct 2-(2- thienyl) -1,3,4- oxadiazoles method | 桂林理工大学 | 2019-02-01 | — | — | CN | claimed |
| CN-115850241-B | Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof | 中国药科大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-119161335-A | Azole derivative containing double bond structure and application thereof | 沈阳药科大学 | 2024-12-20 | — | — | CN | disclosed |
| US-20240391901-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-11-28 | — | — | US | disclosed |
| CN-116438174-A | Compounds and their use as MIF inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-115850241-A | Substituted heterocyclic compound containing alpha-ketone skeleton and application thereof | 中国药科大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-109293650-A | Using DMF as one step of carbon source construct 2-(2- thienyl) -1,3,4- oxadiazoles method | 桂林理工大学 | 2019-02-01 | — | — | CN | disclosed |
| CN-109293650-A | Using DMF as one step of carbon source construct 2-(2- thienyl) -1,3,4- oxadiazoles method | 桂林理工大学 | 2019-02-01 | — | — | CN | disclosed |
| CN-109293650-A | Using DMF as one step of carbon source construct 2-(2- thienyl) -1,3,4- oxadiazoles method | 桂林理工大学 | 2019-02-01 | — | — | CN | disclosed |
| EP-1976512-B1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| CN-101528726-A | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-09 | — | — | CN | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
| EP-2069322-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-1976512-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| CN-101014594-A | Piperidine derivatives as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2007-08-08 | — | — | CN | disclosed |
| WO-2007080542-A1 | NOVEL THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-07-19 | — | — | WO | disclosed |
| CN-1143958-A | (4,4-difluorobut-3-enylthio-)-substituted heterocyclic or carbocyclic ring compounds | ZENECA LTD (GB) | 1997-02-26 | — | — | CN | disclosed |
| EP-0003960-B1 | 6-SUBSTITUTED THIA-AZA-COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884682-B2 | Compounds and their uses as MIF inhibitors | MIF, CCL11, CCL2 | KDM4E 2841/4885RAB9A 3018/4885ALDH1A1 657/4885 |
| US-20240391901-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING ALPHA-KETONE FRAMEWORK, AND USE THEREOF | FAAH, FAAH2, FAH | KDM4E 1478/4885RAB9A 287/4885ALDH1A1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.